A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults
PHASE1CompletedINTERVENTIONAL
Enrollment
18
Participants
Timeline
Start Date
July 28, 2021
Primary Completion Date
August 2, 2022
Study Completion Date
August 2, 2022
Conditions
Healthy Volunteers
Interventions
DRUG
mRNA-6231
Sterile frozen liquid dispersion for injection
Trial Locations (1)
3004
Nucleus Network Limited, Melbourne
All Listed Sponsors
lead
ModernaTX, Inc.
INDUSTRY
NCT04916431 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults | Biotech Hunter | Biotech Hunter